Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

(2023) Imtiaz A Samjoo et al.   Journal of Comparative Effectiveness Research

The Economic Burden of Multiple Sclerosis in the United States

(2022) Bruce Bebo et al.   NEUROLOGY

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives

(2022) Gary Álvarez Bravo et al.   Cells

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

(2021) Ludwig Kappos et al.   JAMA Neurology

Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis

(2021) Zhuoyi Liu et al.   AUTOIMMUNITY REVIEWS

Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

(2021) Marisa P McGinley et al.   LANCET

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

(2021) Simone Huygens et al.   VALUE IN HEALTH

Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis

(2021) Matthijs M. Versteegh et al.   VALUE IN HEALTH

Exploiting relationships between outcomes in Bayesian multivariate network meta‐analysis with an application to relapsing‐remitting multiple sclerosis

(2020) Ed Waddingham et al.   STATISTICS IN MEDICINE

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

(2020) Imtiaz A Samjoo et al.   Journal of Comparative Effectiveness Research

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

(2019) Huihui Li et al.   JOURNAL OF NEUROLOGY

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis

(2019) Rachael McCool et al.   Multiple Sclerosis and Related Disorders

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

EDSS progression assessment heterogeneity in MS according to geographical areas

(2018) F. Bovis et al.   ANNALS OF NEUROLOGY

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

(2017) Bernard Uitdehaag et al.   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

(2017) Bernard Uitdehaag et al.   Multiple Sclerosis Journal

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Affordability of medicines in the European Union

(2017) Tomasz Zaprutko et al.   PLoS One

Cost–utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease

(2016) Peter J Donovan et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

(2016) Stacy Ellen Hatcher et al.   JAMA Neurology

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

(2014) Emanuela Colombo et al.   ANNALS OF NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE